学术论文

      Guideline of Prevention and Treatment for Chronic Hepatitis B (2nd Version)

      摘要:
      This guideline is established to standardize the prevention,diagnosis and antiviral therapy of chronic hepatitis B (CHB).For other treatment regimens and methods involving CHB,please refer to relevant guidelines and consensuses. The Chinese Society of Hepatology,Chinese Medical Association (CMA) and the Society of Infectious Diseases,CMA organized relevant native experts to establish this Guideline of Prevention and Treatment for Chronic Hepatitis B (1st version) in 2005,and made the first revision in 2010.In the past 5 years,great progress has been made in the native and foreign fundamental and clinical research with respect to CHB,necessitating additional revision of this guideline.
      Author: Jinlin Hou [1] Guiqiang Wang [2] Fusheng Wang [3] Jun Cheng [4] Hong Ren [5] Hui Zhuang [6] Jian Sun [1] Lanjuan Li [7] Jie Li [6] Qinghua Meng [8] Jingmin Zhao [9] Zhongping Duan [10] Jidong Jia [11] Hong Tang [12] Jifang Sheng [7] Jie Peng [1] Fengmin Lu [6] Qing Xie [13] Lai Wei [14]
      作者单位: Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China Department of Infectious Diseases, Center for Liver Diseases, Peking University First Hospital, Beijing, China The Institute of Translational Hepatology, 302 Hospital of PLA, Peking University, Beijing, China Center of Liver Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China Institute for Viral Hepatitis, the Key Laboratory of Molecular Biology for Infectious Diseases, the second Affiliated Hospital of Chongqing Medical University, Chongqing, China Department of Microbiology of Peking University Health Science Center, Beijing, China State Key Laboratory for Diagnosis and Treatment of Infectious Diseases,Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China Serious Illness Medicine Inpatient Area, Beijing Youan Hospital, Capital Medical University, Beijing, China Department of Pathology, 302 Hospital of PLA, Peking University, Beijing, China Artificial Liver Center, Beijing Youan Hospital, Capital Medical University, Beijing, China Liver Research Center, Beijing Friendship Hospital,Capital Medical University, Beijing, China Center of Infectious Diseases, West China Hospital of Sichuan University, Division of Infectious Diseases, State Key Laboratory of Biotherapy, Sichuan University, Chengdu, China Department of Infectious Diseases, Shanghai Jiao Tong University School of Medicine Affiliated Ruijin Hospital, Shanghai, China Hepatology Institute,Peking University People's Hospital, Beijing, China
      年,卷(期): 2017, 5(4)
      在线出版日期: 2017年12月18日